Industry News

Rapid Medical Diagnostic Kits Market to Top USD 23 Billion by 2031 due to Successive Outbreaks of Novel Contagious Viruses

By Labmedica International staff writers
01 Nov 2021

Illustration

The global rapid medical diagnostic kits market is projected to grow at a CAGR of 4% over the forecast period 2021-2031 to surpass USD 23.1 billion in 2031, driven by the rising prevalence of infectious diseases such as influenza, COVID-19, and others.


Surging application of rapid medical diagnostic kits in substance abuse testing, homecare settings, fertility & pregnancy testing, and veterinary settings is anticipated to further facilitate the market growth over the assessment period. These are the latest findings of Fact.MR (Rockville, MD, USA), a market research and competitive intelligence provider.


In response to the rising prevalence of infectious diseases, the demand for effective testing devices with faster turnaround time has increased. This is expected to create growth opportunities for the market over the coming years. The market is expected to gain traction as an increasing number companies are focusing on receiving approvals to commercially launch their products. The blood glucose testing application is expected to create new growth frontiers for the rapid medical diagnostic kits market through 2031. The blood glucose testing segment is projected to grow by 2x through 2031. Growing diabetic population and rising demand for self-testing devices for monitoring glucose levels at home are key the factors driving the segment’s growth.


Based on test, infectious disease testing is expected to remain a highly remunerative segment, accounting for more than 40% of the total sales by 2031 end. In terms of application, homecare settings is projected to hold contribute 30% of the total revenues by 2021 end. Additionally, the burgeoning adoption of diagnostics kits for testing pregnancies and rising awareness regarding unwanted pregnancies is spurring the sales of rapid medical diagnostic kits across the fertility & pregnancy testing segment. Moreover, increasing research and development activities for developing novel therapeutics for the treatment of various infectious diseases across the US, China, Japan, and India is expected to propel the demand for rapid medical diagnostic kits.


Geographically, the US is anticipated to remain the dominant market for rapid medical diagnostic kits in North America, accounting for nearly 30% of overall sales over the assessment period. China is estimated to witness the fastest growth in the global rapid medical diagnostic kits market, expanding at a CAGR of 7% between 2021 and 2031. Japan is forecasted to account for a substantial revenue share of the East Asia market for rapid medical diagnostic kits, with a projected sales CAGR of 5% through 2031.


“Successive outbreak of novel contagious viruses such as Hantavirus, Ebola, and others along with mutations in COVID-19 and other pathological genes are expected to increase the demand for point-of-care diagnostic solutions. This is expected to augment the growth in the market,” stated a Fact.MR analyst.


Related Links:
Fact.MR 



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

21 Jan 2022
Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases
The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application of immunofluorescence assays in clinical diagnostics and research, and growing investments and expenditure in healthcare sector.
Read More
21 Jan 2022
Global Digital X-Ray Systems Market to Be Driven by AI-Based Systems and Robotic Devices
The global digital X-ray systems market was valued at USD 11.74 billion in 2020 and is expected to grow at a CAGR of 7.45% during the forecast period 2021 to 2026, due to the rising number of cancer patients and increasing cases of orthopedic diseases/tumors, cardiovascular diseases (CVD), pneumonia, and dental disorders, among others.
Read More
20 Jan 2022
Illumina and Boehringer Ingelheim Partner to Develop Companion Diagnostics (CDx) for Cancer Treatment
Illumina Inc. (San Diego, CA, USA) has entered into a partnership with Boehringer Ingelheim (Ingelheim am Rhein, Germany; www.boehringer-ingelheim.com) to develop companion diagnostics (CDx) for several programs in the latter’s oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.
Read More
20 Jan 2022
Thermo Fisher and Oncocyte to Jointly Develop IVD Test Kits and Companion Diagnostic Tests in Precision Oncology
Oncocyte Corporation (Irvine, CA, USA) has entered into a development and co-marketing agreement for two distributed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s (Waltham, MA, USA) Ion Torrent Genexus System. The agreement also grants Oncocyte rights to develop future companion diagnostics on the Genexus System.
Read More
18 Jan 2022
Global Coagulation Analyzers Market Driven by Growing Awareness About Timely Diagnosis of Blood Clots
The global coagulation analyzers market is expected to reach USD 11.7 billion by 2028, driven by the increasing understanding of blood clots and the fact that they can be avoided with early detection.
Read More
17 Jan 2022
Mobile C-Arms Market to Surpass USD 1.6 Billion in 2027 Due to Growing Preference for Minimally Invasive Surgeries
The global mobile C-arms market is expected to grow at a CAGR of 5.2% from USD 1.07 billion in 2019 to USD 1.61 billion in 2027, driven primarily by an increase in the global geriatric population, rising burden of chronic and acute diseases across the world, increasing volumes of orthopedic, cardiac, neurological, and oncological surgical procedures, and growing preference for minimally invasive surgeries.
Read More
14 Jan 2022
Medlab Middle East to Reveal Latest Innovations and Technologies in Mobile Labs for COVID-19 Testing
The latest technology and innovation in the global fight against COVID-19 and beyond will be on show at the next edition of Medlab Middle East when it returns to the Dubai World Trade Center from 24-27 January 2022 with mobile molecular testing and diagnosis stations, or ‘laboratories on wheels’, from companies such as Seegene, Inc. (Seoul, Korea) taking center stage.
Read More
13 Jan 2022
Global Coagulometers Market to Be Driven by Rising Prevalence of Blood Disorders
The global coagulometers market is being driven by a rise in the incidence and prevalence of blood disorders such as hemophilia that is fueling the demand for more diagnostic tools.
Read More
11 Jan 2022
Medlab Middle East to Return as Standalone Event in 2023
Informa Markets (London, UK), organizers of Medlab Middle East, have announced that the MENA region’s leading exhibition for the laboratory industry will return to a standalone event in 2023.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions